Myriad Genetics (MYGN) News
NASDAQ: MYGNHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
4.31+0.11 (+2.62%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
MYGN news summary
We found 3 recent headlines mentioning Myriad Genetics (MYGN): 3 in the past week and 3 in the past 30 days, most often from Nasdaq, GlobeNewswire. For price context, MYGN is up 2.62% at $4.31. The most recent story, "Myriad Genetics, SOPHiA GENETICS Partner With AstraZeneca On Prostate Cancer PrGIS", was published by Nasdaq on Oct 8, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Myriad Genetics headlines
- Myriad Genetics, SOPHiA GENETICS Partner With AstraZeneca On Prostate Cancer PrGIS(RTTNews) - Myriad Genetics (MYGN) and SOPHiA GENETICS (SOPH) announced a collaboration with AstraZeneca (AZN) to advance a new prostate cancer-specific genomic instability score, or PrGIS, for…NasdaqAZN, MYGN, SOPH
- SOPHiA GENETICS Partners Myriad Genetics To Advance Prostate Genomic Instability Score Technology(RTTNews) - SOPHiA GENETICS (SOPH) and Myriad Genetics, Inc. (MYGN) announced Thursday a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support…NasdaqMYGN, SOPH
- Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score TechnologyMyriad announces new collaboration to advance prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology and CDx.GlobeNewswire